Abstract
Fusion detection stratified by cancer indications with and without FDA-approved targeted therapy. A, Fusions detected in FDA-approved and non–FDA-approved indications aggregated across fusion drivers (see Supplementary Table S1). B, Percent of driver fusions detected by analyte for FDA-approved and non–FDA-approved indications. C, Counts of fusions detected in FDA-approved and non–FDA-approved indications by fusion driver.